SunTrust analyst Bruce Nudell raised his price target on Merit Medical to $62 and kept his Buy rating, saying he is positive on the company's strategy of continued innovation in its "commoditized product segments" as well as the "gradual movement into higher margin therapeutic areas". The analyst adds the company is transitioning to a strategy of "owning a procedure" from incision to closure while making efforts toward "steady margin improvement". Nudell anticipates annual 9.5% growth in revenues and 18.5% in earnings through FY21 in modeling a higher price target, but also warns about risks around pricing in Merit Medical's commoditized segments and potential "M&A missteps".